They are treatments for Alzheimer’s disease, psoriasis, prostate cancer and heart failure
Drug developers are advancing treatments for chronic and progressive diseases that affect millions of patients worldwide, such as Alzheimer’s disease, psoriasis, prostate cancer, and congestive heart failure.
The “Clarivate Drugs” report that is worth a look highlights the four major blockbusters that may appear in the drugs released in 2021.
The report also provides forecasts for the emerging areas of COVID-19 vaccines, which have received emergency use permits and conditional approvals.
Clarivate Plc (NYSE: CLVT), Has released the annual “drugs of concern” list, which identifies the drugs that enter the market or launch key indications in 2021 and are expected to reach the best-selling status in 2025.
A drug in use can make mice lose 40% of their body weight
In addition to the unprecedented achievements of the industry’s response to COVID-19, drug developers have also carried out advanced and epoch-making treatments for diseases that affect millions of patients around the world. The list of drugs to watch this year and related comments focus on the treatment of chronic, progressive and often debilitating diseases and conditions, such as Alzheimer’s disease, prostate cancer and congestive heart failure.
Despite a difficult year, biopharmaceutical companies have managed to produce highly effective vaccines and treatments that can prevent SARS-CoV-2. This year’s “Observation of Drugs” report also outlines the emerging COVID-19 vaccine field, outlines the vaccines that have received emergency use licenses/conditional approvals as of February 10, 2021, and the industry’s experience in some adjustments to this Lessons learned that the trend leading to the COVID-19 pandemic may greatly surpass the immediate crisis and affect the R&D and commercialization of biopharmaceuticals, including: faster clinical trials, massive investment, greater cooperation, and long-distance attention and consultation .
Among the new drugs and biologics that have been or will be approved, Clarivate has identified four therapies that may reach the best-selling status within five years, with annual sales of more than $1 billion. The 2021 drugs that will be introduced are:
Aducanumab, jointly developed by Biogen and Eisai, may change the rules of the game, thereby changing the anti-Alzheimer’s disease pharmacopoeia, which is estimated to affect 50 million patients worldwide.
If approved, Adunazumab will become the first disease-modified treatment for Alzheimer’s disease, and it may provide a huge opportunity to completely change the way patients care and transform the market. If approved, the demand for treatment will be huge, and it may even reduce the willingness to abandon the use of this therapeutic drug in future clinical trials and switch to the investigational drug.
Bimekizumab, developed by UCB, can significantly reduce the side effects of patients with psoriasis, which is a disease that is estimated to affect 2-3% of the global population, as well as many other autoimmune diseases. Although bimekizumab is the most advanced product that can provide gradual improvements to existing treatments, it is expected to have best-in-class efficacy and reduce serious side effects.
Relugolix developed by Takeda is one of the first drugs in new therapies. Its oral preparation can treat prostate cancer, the second most common malignant tumor affecting men, and diseases such as endometriosis and uterine fibroids, affecting hundreds of Million women. It can be used for three indications to increase your chances of success. Oral formulations offer advantages over competitive injectable GnRH agonists, such as convenience and better side-effect control.
Vericiguat, developed by Bayer and Merck, is an innovative treatment for heart failure. It is the first treatment specifically for chronic heart failure with high ejection and reduced ejection fraction (ICrEF), which is particularly at risk. Vericiguat’s novel mechanism of action should allow it to be accepted as a complementary therapy to existing therapies. It may find its place in high-risk rHF patients, become a welcome addition to the treatment library, and expand your treatment options.
In the past five years, the number of approvals for innovative drugs has more than tripled compared to a decade ago. In order to achieve this improvement, many factors have been combined, including a deeper understanding of the biological roots of the disease, cancer research benefiting from the introduction of conventional biomarkers to better guide treatment, the emergence of gene and cell therapies, and supervision Work hard. The agency introduced a process to speed up drug evaluation.